Baxter Investors Urged to Seek Lead Role in Novum Pump Securities Cases Before Dec. 15 Deadline

Filings cite alleged concealment of Novum infusion‑pump defects that preceded a shipment pause, triggering a sharp share decline.

Overview

Rosen Law Firm, Bernstein Liebhard, Lowey Dannenberg, and Robbins LLP are soliciting Baxter shareholders to move for lead‑plaintiff status by December 15, 2025.
A complaint filed on October 16, 2025 in the Northern District of Illinois alleges Baxter misled investors about systemic Novum LVP malfunctions, including underinfusion, overinfusion, and non‑delivery linked to injuries and deaths.
Plaintiffs assert Baxter’s customer alerts were inadequate while design flaws persisted, creating a risk that devices would be pulled from service or new sales would be paused.
Baxter announced on July 31, 2025 that it would temporarily pause Novum LVP shipments and installations, and the stock fell 22.4% to close at $21.76 that day.
Most notices define the class period as February 23, 2022 through July 30, 2025, though at least one outreach references a different window, and no class has been certified.